Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05927428 · ClinicalTrials.gov registry record · Phase 2
Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis
A Phase 2 study of Neurotrophic Keratitis, sponsored by BRIM Biotechnology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05927428: Recruiting Phase 2 study of Neurotrophic Keratitis, sponsored by BRIM Biotechnology.
NCT05927428 is a Phase 2 study of Neurotrophic Keratitis that is actively recruiting participants, run by BRIM Biotechnology. The registered enrollment target is 12 participants, below the 22-participant average among 6 other Neurotrophic Keratitis trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05927428, a Phase 2 study of Neurotrophic Keratitis, is actively recruiting participants, sponsored by BRIM Biotechnology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
Conditions Studied
Interventions
- DRUG BRM424 Ophthalmic Solution - Dose1
- DRUG BRM424 Ophthalmic Solution - Dose2
Study Locations (1)
North Carolina
- Wilmington Eye - Leland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2025-11-30 |
| Phase | Phase 2 |
What NCT05927428 shows while recruiting
NCT05927428 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 22-participant average among 6 other Neurotrophic Keratitis trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Neurotrophic Keratitis appearing as the primary indexed condition, and to 2 interventions - of which BRM424 Ophthalmic Solution - Dose1 is the first listed.
NCT05927428 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05927428 about?
NCT05927428 is a clinical study titled "Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis". The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.
What is the current status of trial NCT05927428?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2024-07-31. Estimated completion is 2025-11-30.
What conditions does trial NCT05927428 study?
This clinical trial studies the following conditions: Neurotrophic Keratitis.
What interventions are being tested in trial NCT05927428?
The interventions under investigation include: BRM424 Ophthalmic Solution - Dose1 (DRUG), BRM424 Ophthalmic Solution - Dose2 (DRUG).
Who is sponsoring clinical trial NCT05927428?
This trial is sponsored by BRIM Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05927428 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurotrophic Keratitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
RECRUITING · Phase 1
-
OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate
RECRUITING
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
DOMPE -MT Neurotrophic Keratitis
ACTIVE NOT RECRUITING · Phase 4
-
Corneal Nerves After Treatment With Cenegermin
COMPLETED
-
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI